LEO Pharma said on August 5 that it has received Japanese regulatory approval for an auto-injector pen form of Adtralza (tralokinumab), an antibody therapy for atopic dermatitis. The new version was approved on July 31 for the indication of atopic…
To read the full story
Related Article
- LEO Pharma’s Adtralza Pen Version Now Available in Japan
December 3, 2024
- LEO Pharma’s Eczema Drug Adtralza OK’ed for Self-Injection
March 14, 2024
- LEO Pharma’s Eczema Drug Adtralza Now Available in Japan
September 27, 2023
BUSINESS
- Lilly Confirms Orforglipron Diabetes Filings in US, Japan
August 7, 2026
- Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
- Inrebic Expands First-Line Treatment Options for Myelofibrosis: Expert
August 7, 2026
- Meiji Pharma Drops Hiyasta Development in B-Cell NHL
August 7, 2026
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





